Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Inhaled XW001 (Interleukin 29 Analog for Nebulization) For Hospitalized COVID-19 Patients Requiring Oxygen Therapy: A Multiregional, Randomized, Double-blind, Placebo-controlled Study

NCT05083117 is registered in ClinicalTrials.gov with Sciwind Biosciences APAC CO Pty. Ltd. as lead sponsor.

NCT NCT05083117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05083117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Inhaled XW001 (Interleukin 29 Analog for Nebulization) For Hospitalized COVID-19 Patients Requiring Oxygen Therapy: A Multiregional, Randomized, Double-blind, Placebo-controlled Study
Lead sponsor
Sciwind Biosciences APAC CO Pty. Ltd.
Phase
Phase 2
Overall status
Withdrawn
Start date
October 30, 2021
Completion date
April 10, 2022
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 acute respiratory distress syndrome